UBS O'Connor’s Evolent Health EVH Stock Holding History

UBS O'Connor’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-220,995	Closed	-$3.93M	–	317
2017 Q3	$3.93M	Buy	+220,995	New	+$4.55M	0.06%	211

Other funds holding EVH

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Formula Growth Montreal, Quebec, Canada $222M AUM 27.84% 1-Year Est. Return

UBS O'Connor's EVH Position: Q4 2017 in Review

UBS O'Connor sold out of Evolent Health (EVH) in Q4 2017, closing a stake of 220,995 shares — an estimated $3.93M sold.

UBS O'Connor first reported a position in EVH in Q3 2017 and held it in 1 quarter. The position peaked at $3.93M in Q3 2017. 156 funds tracked by Wall St. Rank hold EVH as of Q4 2017.

UBS O'Connor reported no remaining Evolent Health position as of Q4 2017 after selling out during the quarter.
UBS O'Connor sold 220,995 Evolent Health shares in Q4 2017, an estimated $3.93M.
UBS O'Connor first reported a position in Evolent Health in Q3 2017 and held it in 1 quarter.
UBS O'Connor's Evolent Health position peaked at $3.93M in Q3 2017.
156 funds tracked by Wall St. Rank held Evolent Health as of Q4 2017.

Based on UBS O'Connor's 13F filing for Q4 2017, filed 14 Feb 2018.